IPP Bureau
Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
By IPP Bureau - January 07, 2024
This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
Omniose collaborates with AstraZeneca to research vaccines for serious bacterial diseases
By IPP Bureau - January 07, 2024
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
AOB Pharma and Maruho enter into an agreement for AOB’s B244 for treatment of atopic dermatitis in Japan
By IPP Bureau - January 07, 2024
The deal includes upfront payments, milestone payments and ongoing royalties
Jiangsu Vcare files NDA for Vicagrel Capsules with USFDA
By IPP Bureau - January 06, 2024
Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
By IPP Bureau - January 06, 2024
Comprehensive clinical development programs being initiated for each investigational candidate
Servier and Base4 partner to advance neuroscience drug development
By IPP Bureau - January 06, 2024
Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
Supriya Lifesciences received GMP certification from ANVISA Brazil
By IPP Bureau - January 06, 2024
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Hyderabad to host 66th All India Congress of Obstetrics and Gynaecology 2024
By IPP Bureau - January 05, 2024
The congress aims at emphasizing on the most recent trends, advancements in the field of Obstetrics & Gynaecology
PayNearby, Star Health join forces to provide health cover to uninsured across Bharat
By IPP Bureau - January 05, 2024
Star Health's convenient claims process, valued added offerings like free telemedicine consultations with expert doctors
Lupin receives tentative approval from USFDA for Dapagliflozin and Saxagliptin tablets
By IPP Bureau - January 04, 2024
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
CCRAS launches ‘SMART 2.0’ for ayurveda teaching professionals
By IPP Bureau - January 04, 2024
Medway Hospitals raises US$5 million in a financing round led by Kyra Ventures
By IPP Bureau - January 04, 2024
Medway setup a state-of-the-art Heart Institute in Chennai
Mandaviya lays foundation stone for NCDC regional branch, state branches and 2 BSL-3 laboratories
By IPP Bureau - January 03, 2024
Dedicates upgraded National Centre for Disease Control, Delhi and a Temporary Regional Branch of NCDC to the nation
India screens 1 crore+ person for Sickle Cell Disease
By IPP Bureau - January 03, 2024
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
By IPP Bureau - January 03, 2024
The company has received five final approvals
